6335-44-0

Upstream product

• 15118-70-4 ethyl 4-(4-nitrophenyl)-4-oxobutanoate 

Downstream Products

• 430440-78-1 ethyl 4-(4-{[(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)methyl]amino}phenyl)-4-oxobutanoate 
• 136912-52-2 ethyl 4-oxo-4-<2-<(3-chlorobenzoyl)oxy>-3,4-dihydro-3-oxo-2H-1,4-benzothiazin-7-yl>butyrate 
• 136912-43-1 4-(4-Amino-3-mercapto-phenyl)-4-oxo-butyric acid ethyl ester 

Relevant academic research and scientific papers

Pharmaceutically active benzoquinazoline compounds

Compounds of formula (I) or salts thereof, wherein the dotted line represents a single or double bond, R1is alkyl or amino optionally substituted by alkyl, alkanoyl or benzyl group; R2, R3, R4and R5are the same or different and each is selected from hydrogen, phenyl, halo, nitro, a group S(O)nR8wherein n is the integer 0, 1 or 2 and R8is halo or alkyl or a group NR9R10wherein R9and R10are both hydrogen, a group NR11R12wherein R11and R12are the same or different and each is hydrogen or alkyl, a group OR13wherein R13is hydrogen or C1-4alkyl optionally substituted by halo; a C1-4aliphatic group optionally substituted by a group OR14or NR14R15wherein R14and R15are the same or different and each is hydrogen or alkyl; or two of R2to R5are linked together to form a benzo group, or one of R2to R5is a group -X-Y-R16wherein X is CH2, NR17, CO or S(O)m, and Y is CH2, NR17, O, or S(O)m, or -X-Y- is a group -O-, -NR17-, -CH=CH- or -N=N-, are disclosed as pharmacological agents useful in the treatment of tumours. Pharmaceutical compositions and methods for the preparation of compounds of formula (I) are also described.

1-arylsulphonyl, arylcarbonyl and 1-arylphosphonyl-3-phenyl-1,4,5,6-tetrahydropyridazines

Disclosed are progestin agonists having the following formula: STR1 W is absent or --CH=CH--; R1 are independently selected from the group consisting of halogen, --CF3, and NO2, or both R1 may be joined to form a bi-radical which is --CH=CHCH=CH--; R3 are independently selected from the group consisting of hydrogen, C1-6 branched or linear alkyl, halogen and --CF3, with the proviso that R3 at the 3-position must be H where R3 at the 4-position is H, or both R3 may be joined to form a bi-radical selected from the group consisting of --CH=CHCH=CH--, --C(NC1-4 alkyl2)=CHCH=CH-- and --(CH2)4 --; R5 is selected from the group consisting of H and Me; with the proviso that only one of R1 and R3 forms the fused bi-radical; and the stereoisomers.

PHARMACEUTICAL COMPOUNDS

The present invention relates to novel benzoquinazoline thymidylate synthase inhibitors, to pharmaceutical formulations containing them and to their use in medicine